4th Quarter - Report

AMGEN, INC. for AMGEN INC

Firm
Client
Income
—
Expenses
$1,970,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Research and experimentation tax incentives and international tax issues, including: President's Fiscal Year 2015 Budget, Tax Reform, including House Ways and Means and Senate Finance Committee Discussion Drafts H.R. 4438 American Research and Competitiveness Act H.R. 4464 Permanent CFC-Look-Through Act S. 2260 Expiring Provisions Improvement, Reform and Efficiency (Expire) Act H.R. 4 Jobs for America Act H.R. 5771, The Tax Increase Prevention Act

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
L NICOLE CURRIE —
NANCY ELLEN MCCARTHY —
HELEN RHEE —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4464 (113th), H.R. 4438 (113th), H.R. 4 (113th), S. 2260 (113th), H.R. 5771 (113th)

Copyright/Patent/Trademark CPT

H.R. 3309 The Innovation Act of 2013 (heightened pleading standards, discovery stay) S. 1720, The Patent Transparency and Improvements Act (demand letters, customer stay) S. 1013, The Patent Abuse Reduction Act (heightened pleading standards, discovery stay) S. 1612, The Patent Litigation Integrity Act (bonding) Trans-Pacific Partnership (12 years data exclusivity) S. 866, The Patient Quality Improvement Act (covered business method patents) Patent Reform, no specific bill

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
L NICOLE CURRIE —
RUTH HOFFMAN —
JESSE KERNS —
REBECCA MANDELL —
HOWARD MOON —
WILLIAM O'BRIEN —
GREGORY PORTNER —
HELEN RHEE —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 3309 (113th), S. 1720 (113th), S. 866 (113th), S. 1013 (113th), S. 1612 (113th)

Health Issues HCR

Biosimilars, no specific bill Health Resources and Services Administration (HRSA) policy regarding rebates on drugs used in the outpatient setting to help low-income/uninsured populations (340B), no specific bill FDA Reform, no specific bill

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
L NICOLE CURRIE —
RUTH HOFFMAN —
JESSE KERNS —
REBECCA MANDELL —
HOWARD MOON —
WILLIAM O'BRIEN —
GREGORY PORTNER —
HELEN RHEE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Medicare/Medicaid MMM

Medicare Part B drug reimbursement issues (Average Sales Price) 2015 Labor/HHS Senate Appropriations draft committee report (340B drug pricing program) Public Law No. 113-164, Continuing Appropriations Resolution, 2015 (340B, Medicare Orphan Drug Issue)

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
L NICOLE CURRIE —
RUTH HOFFMAN —
JESSE KERNS —
REBECCA MANDELL —
HOWARD MOON —
WILLIAM O'BRIEN —
GREGORY PORTNER —
HELEN RHEE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.